MYND Life Sciences announces DTC eligibility

VANCOUVER, BC, August 11, 2021 / PRNewswire / – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development company focused on the development of novel psychedelic drugs, diagnostic approaches, pharmaceuticals and vaccines, is pleased to announce that it is now eligible for the services of The Depository Trust Company (” DTC ”) in connection with the registration of the company on the OTC. Thanks to the OTC listing, investors in the United States can more easily trade MYNDF stock, in addition to listing MYND on the CSE “MYND” in Canada.

“We are delighted to receive DTC eligibility, which not only allows the Company access to a wider range of US-based investors, but also provides US investors with additional opportunities to acquire stocks. MYND, ”said MYND CEO Dr. Lyle Oberg. “There are 300 million people worldwide with major depressive disorder and other related conditions who have not been well served by the existing class of SSRIs to treat depression. We are confident that we have the capacity. science, intellectual property and law leadership to achieve the first substantive innovation in this class of drugs in a generation. ”

DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages electronic clearing and settlement of listed companies. MYND is now eligible for clearing and electronic settlement, which will streamline the trading process, improve liquidity and provide direct access to investors in United States OTC capital markets.

For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES

MYND Life Sciences is a medical biotechnology company specializing in the development of neuropharmaceutical drugs. The Company advances medicinal substances through rigorous scientific and clinical trials.

CONTACT INFORMATION
Dr. Lyle Oberg, CEO
Email: [email protected]
Web: www.myndsciences.com

Forward-looking statements

This press release contains forward-looking statements and information within the meaning of applicable securities laws. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “believes”, “Intention”, “” anticipates “or” does not anticipate “, or” believes “, or variations of these words and expressions or declares that certain actions, events or results” could “,” could “,” would be “,” could “or” would “be made, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of MYND are materially different from the future results, performances or achievements expressed or implied by the forward-looking statements or information contained in this press release.

The risks, uncertainties and other factors involved in forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/mynd-life-sciences-announces-dtc-eligibility-301353150.html

SOURCE Mynd Life Sciences Inc.


Source link

Margie D. Carlisle

Leave a Reply

Your email address will not be published. Required fields are marked *